TransCure bioServices is a European contract research organisation (CRO) based in Archamps, France, offering preclinical in vivo pharmacology fee-for-service using uniquely designed full human immune system and hu-liver mouse models. Its core offerings target immuno-oncology, inflammation (IBD, SLE, MS, RA), autoimmune and infectious diseases (including HIV), liver diseases, and vaccines, and support applications such as checkpoint inhibition, CAR-T designs, and 100% human IgG monoclonal antibody profiling. The company reports it has been healthy and profitable for the last three years and has generated significant growth over that period. The new funding is intended to accelerate international sales growth, expand in vivo preclinical pharmacology services into new product lines, and strengthen the commercial team. TransCure plans to use proceeds to expand its profitable business activities in Europe and the USA and to develop additional platforms for international pharmaceutical and biotech companies, including new hu-liver and 100% human monoclonal antibody services. Agile Capital Markets acted as financial advisor for the transaction.

Total raised

$3M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2019